A Phase 3 interventional study of Povorcitinib and Placebo in NonSegmental Vitiligo, sponsored by Incyte Corporation. Active, not recruiting at 86 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Vitiligo by Incyte Corporation — 2 open to participants now, 4 under way, 4 of them phase 3. Vitiligo · Incyte Corporation.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 3rd largest by enrollment, is one of 3 that started in 2023, is one of 7 in phase 3, and was the 9th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →2 of the 12 studies in Vitiligo by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
By country, each count listing its studies:
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 450 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 215 across the 12 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Vitiligo by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Vitiligo by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of nonsegmental vitiligo and meet the following:
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
Drug: Povorcitinib
Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
Drug: Placebo
Oral, Tablet
Also known as: INCB054707
Oral, Tablet
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)
≥75% improvement in facial Vitiligo Area Scoring Index.
Time frame: Week 52
Percentage change from Baseline in Total Body Vitiligo Area Scoring Index (T-VASI)
Percentage change from Baseline in total body Vitiligo Area Scoring Index.
Time frame: Week 52
Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50)
≥50% improvement in total body Vitiligo Area Scoring Index.
Time frame: Week 52
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75)
≥75% improvement in total body Vitiligo Area Scoring Index.
Time frame: Week 52
Proportion of participants achieving a Vitiligo Noticeability Scale Score (VNS) of 4 or 5
VNS is a participant reported outcome measure on a scale of 1-5, 1- more noticeable, 4 - a lot less noticeable, and 5- no longer noticeable.
Time frame: Week 52 and Week 104
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
Time frame: Up to Week 104 and 30 days
Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI50)
≥50% improvement in facial Vitiligo Area Scoring Index.
Time frame: Week 52 and Week 104
Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI75)
≥75% improvement in facial Vitiligo Area Scoring Index.
Time frame: Week 104
Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VAS190)
≥90% improvement in facial Vitiligo Area Scoring Index.
Time frame: Week 52 and Week 104
Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI50)
≥50% improvement in total body Vitiligo Area Scoring Index.
Time frame: Week 104
Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI75)
≥75% improvement in total body Vitiligo Area Scoring Index.
Time frame: Week 104
Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI90)
≥90% improvement in total body Vitiligo Area Scoring Index.
Time frame: Week 52 and Week 104
Proportion of participants achieving an Facial Static Investigator Global Assessment (FSIGA) of 0 or 1
Global score of vitiligo severity for the face. Scores range from 0 (clear) to 5 (severe vitiligo).
Time frame: Week 52 and Week 104
Proportion of participants in each Facial Static Investigator Global Assessment (FSIGA) category
Global score of vitiligo severity for the face. Scores range from 0 (clear) to 5 (severe vitiligo).
Time frame: Week 52 and Week 104
Proportion of participants achieving a Static Investigator Global Assessment (SIGA) of 0 (clear) or 1 (almost clear)
Global score of vitiligo severity for the entire body. Scores range from 0 (clear) to 5 (severe vitiligo).
Time frame: Week 52 and Week 104
Proportion of participants in each Static Investigator Global Assessment (SIGA) category
Global score of vitiligo severity for the entire body. Scores range from 0 (clear) to 5 (severe vitiligo).
Time frame: Week 52 and Week 104
Proportion of participants who report Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V) of 1 or 2
F-PaGIC-V is an assessment of improvement of vitiligo on the face by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).
Time frame: Week 52 and Week 104
Proportion of participants in each Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V) category
F-PaGIC-V is an assessment of improvement of vitiligo on the face by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).
Time frame: Week 52 and Week 104
Proportion of participants who report Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V) of 1 or 2
T-PaGIC-V is an assessment of improvement of vitiligo on the total body by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).
Time frame: Week 52 and Week 104
Proportion of participants in each Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V) category
T-PaGIC-V is an assessment of improvement of vitiligo on the total body by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).
Time frame: Week 52 and Week 104
Proportion of participants in each category for the color-matching question
Participants will answer how well the color of the treated skin matches the normal skin on a scale of 1-5, 1 being excellent to 5 being very poor.
Time frame: Week 52 and Week 104
Change from baseline in the Vitiligo-Specific Quality of Life (VitiQoL)
VitiQoL is a 15-item QoL assessment that asks participants to rate various aspects of their condition during the past month using a 7-point scale ("Not at all" to "All of the time").
Time frame: Week 52 and Week 104
Change from baseline in the Hospital Anxiety and Depression Scale (HADS) subscales
HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3).
Time frame: Week 52 and Week 104
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Nov 2023 to primary completion in Mar 2026, 27 months.
Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib